Alfred Furth

Learn More
BACKGROUND Clinical trials involving patients with glioblastoma (GBM) distinguish cohorts who are treated with enzyme-inducing anticonvulsants (EIAC). Such anticonvulsants induce hepatic P450 microsomal enzymes, which accelerate the metabolism of certain chemotherapy and molecular targeted agents. However, the resultant effect of such induction on patient(More)
The purpose of this study was to establish an accurate and accessible immunohistochemical (IHC) method for detecting vIII Egf receptor and to assess the prognostic significance of the method as applied to the detection of vIII in malignant astrocytomas. The accuracy of the method was determined by comparing vIII immunoreactivity in formalin-fixed and(More)
Although the three-outcome phase II clinical trial design (Sargent et al., 2001) has seen increasing use, confidence interval methodology for the binary endpoint had not been explicitly defined. Typical phase II clinical trial designs with binomial endpoints use a sequential binomial confidence interval (SBCI) algorithm (Duffy and Santner, 1987). We(More)
  • 1